Accessing the inaccessible: Molecular tools for bifidobacteria

Applied and Environmental Microbiology

Volumn 78, Issue 15, 2012, Pages 5035-5042

  Sun, Zhongke ^a,b   Baur, Annika ^a   Zhurina, Daria ^a   Yuan, Jing ^b   Riedel, Christian U ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENEFICIAL EFFECTS; BIFIDOBACTERIA; DELIVERY VECTOR; EXPRESSION VECTORS; FOOD INDUSTRIES; HEALTH STATUS; MICROBIOTAS; MOLECULAR TOOLS; PROBIOTICS; RECOMBINANT STRAINS; SELECTION MARKER; TUMOR THERAPY;

DRUG DELIVERY; HEALTH CARE; VACCINES;

BACTERIA;

LIVE VACCINE; PROBIOTIC AGENT;

BACTERIUM; DRUG; GENE EXPRESSION; HEALTH IMPACT; MOLECULAR ANALYSIS; RECOMBINATION; TUMOR; VACCINATION;

BACTERIUM TRANSFORMATION; BIFIDOBACTERIUM; DRUG DELIVERY SYSTEM; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE; METABOLISM; METHODOLOGY; MICROBIOLOGY; PLASMID; PROMOTER REGION; SHORT SURVEY;

BIFIDOBACTERIUM; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; INTESTINES; PLASMIDS; PROBIOTICS; PROMOTER REGIONS, GENETIC; TRANSFORMATION, BACTERIAL; VACCINES, LIVE, UNATTENUATED;

EID: 84866175125     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00551-12     Document Type: Short Survey

References (92)

1. Alvarez-Martín P, Bel én Flórez A, Margolles A, del Solar G, Mayo B. 2008.Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon.Appl. Environ. Microbiol.74:4656-4665.
2. Alvarez-Martín P, O'Connell-Motherway M, van Sinderen D, Mayo B. 2007. Functional analysis of the pBC1 replicon from B fidobacterium catenulatum L48. Appl. Microbiol. Biotechnol. 76:1395-1402.
3. Argnani A, Leer RJ, van Luijk N, Pouwels PH. 1996. A convenient and reproducible method to genetically transform bacte ia of the genus Bifidobacterium. Microbiology 142(Pt 1):109-114.
4. Baban CK, Cronin M, O'Hanlon D, O'Sullivan GC, Tangney M. 2010. Bacteria as vectors for gene therapy of cancer. Bioeng. Bugs 1:385-394.
5. Charteris WP, Kelly PM, Morelli L, Collins JK. 1998. Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract. Lett. Appl. Microbiol. 26:333-337.
6. Chen Q, et al. 2008. In vitro CpG methylation increases the transforma-tion efficiency of Borrelia burgdorferi strains harboring the endogenous linear plasmid lp56. J. Bacteriol. 190:7885-7891.
7. Ciampi MS. 2006. Rho-dependent terminators and transcription termination. Microbiology 152:2515-2528.
8. Claverys J-P, Prudhomme M, Martin B. 2006. Induction of competence regulons as a general response to stress in Gram-positive bacteria. Annu. Rev. Microbiol. 60:451-475.
9. Cronin M, et al. 2012. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One 7:e30940. doi: 10.1371/journal.pone.0030940.
10. Cronin M, Knobel M, O'Connell Motherway M, Fitzgerald GF, van Sinderen D. 2007. Molecular dissection of a bifidobacterial replicon. Appl. Environ. Microbiol. 73:7858-7866.
11. Cronin M, et al. 2010. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol. Ther. 18:1397-1407.
12. Cronin M, Sleator RD, Hill C, Fitzgerald GF, van Sinderen D. 2008. Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. BMC Microbiol. 8:161.
13. Cronin M, Zomer A, Fitzgerald G, van Sinderen D. 1 May 2012. Identification of iron-regulated genes of Bifidobacterium breve UCC2003 as a basis for controlled gene expression. Bioeng. Bugs [Epub ahead of print.]
14. Dai D, Walker WA. 1999. Protective nutrients and bacterial colonization in the immature human gut. Adv. Pediatr. 46:353-382.
15. Delgado S, Flórez AB, Mayo B. 2005. Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr. Microbiol. 50:202-207.
16. Eckburg PB, et al. 2005. Diversity of the human intestinal microbial flora. Science 308:1635-1638.
17. Fanning S, et al. 2012. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc. Natl. Acad. Sci. U.S.A. 109:2108-2113.
18. Forbes NS. 2010. Engineering the perfect (bacterial) cancer therapy Nat. Rev. Cancer 10:785-794.
19. Fu G-F, et al. 2005. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 12: 133-140.
20. Fukuda S, et al. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543 547.
21. Gill SR, et al. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312:1355-1359.
22. Goshima N, Kano Y, Imamoto F. 1990. Characterization of HU-like protein from Bifidobacterium longum. Biochimie 72:207-212.
23. Groot MN, Nieboer F, Abee T. 2008. Enhanced transformation efficiency of recalcitrant Bacillus cereus and Bacillus weihenstephanensis isolates upon in vitro methylation of plasmid DNA. Appl. Environ. Microbiol. 74:7817-7820.
24. Gueimonde M, Garrigues C, van Sinderen D, de los Reyes-Gavilán CG, Margolles A. 2009. Bile-inducible efflux transporter from Bifidobacterium longum NCC2705, conferring bile resistance. Appl. Environ. Microbiol. 75:3153-3160.
25. Guglielmetti S, Ciranna A, Mora D, Parini C, Karp M. 2008. Construction, characterization and exemplificative application of bioluminescent Bifidobacterium longum biovar longum. Int. J. Food Microbiol. 124:285-290.
26. Hamaji Y, et al. 2007. Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy. Biosci. Biotechnol. Biochem. 71:874-883.
27. Hidaka A, Hamaji Y, Sasaki T, Taniguchi S, Fujimori M. 2007. Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. Biosci. Biotechnol. Biochem. 71:2921-2926.
28. Hu B, et al. 2009. Bifidobacterium longum as a delivery system of TRA and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther. 16:655-663.
29. Hung MN, Xia Z, Hu NT, Lee BH. 2001. Molecular and biochemical analysis of two beta-galactosidases from Bifidobacterium infantis HL96. Appl. Environ. Microbiol. 67:4256-4263.
30. Iwata M, Morishita T. 1989. The presence of plasmids in Bifidobacterium breve. Lett. Appl. Microbiol. 9:165-168.
31. Jensen PR, Hammer K. 1998. The sequence of spacers between the consensus sequences modulates the strength of prokaryotic promoters. Appl. Environ. Microbiol. 64:82-87.
32. Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I. 2007. Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress. Antimicrob. Agents Chemother. 51:169-174.
33. Khokhlova EV, Efimov BA, Kafarskaia LI, Shkoporov AN. 2010. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve. Arch. Microbiol. 192:769-774.
34. Kim G-B, Lee BH. 2008. Genetic analysis of a bile salt hydrolase in Bifidobacterium animalis subsp. lactis KL612. J. Appl. Microbiol. 105:778-790.
35. Kim JY, Wang Y, Park MS, Ji GE. 2010. Improvement of transformation efficiency through in vitro methylation and SacII site mutation of plasmid vector in Bifidobacterium longum MG1. J. Microbiol. Biotechnol. 20:1022-1026.
36. Klijn A, et al. 2006. Construction of a reporter vector for the analysis of Bifidobacterium longum promoters. Appl. Environ. Microbiol. 72:7401-7405.
37. Kurokawa K, et al. 2007. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res. 14:169-181.
38. Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D. 2005. Getting better with bifidobacteria. J. Appl. Microbiol. 98:1303-1315.
39. Lee J-H, O'Sullivan DJ. 2010. Genomic insights into bifidobacteria. Microbiol. Mol. Biol. Rev. 74:378-416.
40. Lee J-H, O'Sullivan DJ. 2006. Sequence analysis of two cryptic plasmids from Bifidobacterium longum DJO10A and construction of a shuttle cloning vector. Appl. Environ. Microbiol. 72:527-535.
41. Li X, et al. 2003. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10:105-111.
42. Long RT, et al. 2010. Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice. Int. J. Obes. (Lond.) 34:712-719.
43. Ma Y, Luo Y, Huang X, Song F, Liu G. 2012. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology 158:498-504.
44. MacConaill LE, Fitzgerald GF, van Sinderen D. 2003. Investigation of protein export in Bifidobacterium breve UCC2003. Appl. Environ. Microbiol. 69:6994-7001.
45. Mackie RI, Sghir A, Gaskins HR. 1999. Developmental microbial ecology of the neonatal gastrointestinal tract. Am. J. Clin. Nutr. 69:1035S-1045S.
46. Malmgren RA, Flanigan CC. 1955. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 15:473-478.
47. Martínez I, et al. 2009. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl. Environ. Microbiol. 75:4175-4184.
48. Matsumura H, Takeuchi A, Kano Y. 1997. Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. Biosci. Biotechnol. Biochem. 61:1211-1212.
49. Missich R, Sgorbati B, LeBlanc DJ. 1994. Transformation of Bifidobacterium longum with pRM2, a constructed Escherichia coli-B. longum shuttle vector. Plasmid 32:208-211.
50. Monk IR, Gahan CGM, Hill C. 2008. Tools for functional postgenomic analysis of Listeria monocytogenes. Appl. Environ. Microbiol. 74:3921-3934.
51. Monk IR, Shah IM, Xu M, Tan M-W, Foster TJ. 2012. Transforming the untransformable: application of direct transformation to manipulate genetically Staphylococcus aureus and Staphylococcus epidermidis. mBio 3:e00277-11. doi:10.1128/mBio.00277-11.
52. Moon G-S, Pyun Y-R, Park MS, Ji GE, Kim WJ. 2005. Secretion of recombinant pediocin PA-1 by Bifidobacterium longum, using the signal sequence for bifidobacterial alpha-amylase. Appl. Environ. Microbiol. 71: 5630-5632.
53. Nakamura T, et al. 2002. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 66:2362-2366.
54. O'Connell Motherway M, et al. 2008. Characterization of ApuB, an extracellular type II amylopullulanase from Bifidobacterium breve UCC2003. Appl. Environ. Microbiol. 74:6271-6279.
55. O'Connell Motherway M, O'Driscoll J, Fitzgerald GF, van Sinderen D. 2009. Overcoming the restriction barrier to plasmid transformation andtargeted mutagenesis in Bifidobacterium breve UCC2003. Microb. Biotechnol. 2:321-332.
56. O'Connell Motherway M, et al. 2011. Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc. Natl. Acad. Sci. U.S.A. 108:11217-11222.
57. O'Riordan K, Fitzgerald GF. 1999. Molecular characterisation of a 5.75-kb cryptic plasmid from Bifidobacterium breve NCFB 2258 and determination of mode of replication. FEMS Microbiol. Lett. 174:285-294.
58. Papagianni M, Avramidis N, Filioussis G. 2007. High efficiency electrotransformation of Lactococcus lactis spp. lactis cells pretreated with lithium acetate and dithiothreitol. BMC Biotechnol. 7:15.
59. Park K-B, Ji G-E, Park M-S, Oh S-H. 2005. Expression of rice glutamate decarboxylase in Bifidobacterium longum enhances gamma-aminobutyric acid production. Biotechnol. Lett. 27:1681-1684.
60. Park MS, Shin DW, Lee KH, Ji GE. 1999. Sequence analysis of plasmid pKJ50 from Bifidobacterium longum. Microbiology 145(Pt 3):585-592.
61. Park MS, Kwon B, Shim JJ, Huh CS, Ji GE. 2008. Heterologous expression of cholesterol oxidase in Bifidobacterium longum under the control of 16S rRNA gene promoter of bifidobacteria. Biotechnol. Lett. 30:165-172.
62. Park MS, Moon HW, Ji GE. 2003. Molecular characterization of plasmid from Bifidobacterium longum. J. Microbiol. Biotechnol. 13:457-462.
63. Pokusaeva K, Fitzgerald GF, van Sinderen D. 2011. Carbohydrate metabolism in Bifidobacteria. Genes Nutr. 6:285-306.
64. Pokusaeva K, et al. 2010. Ribose utilization by the human commensal Bifidobacterium breve UCC2003. Microb. Biotechnol. 3:311-323.
65. Pokusaeva K, et al. 2011. Cellodextrin utilization by Bifidobacterium breve UCC2003. Appl. Environ. Microbiol. 77:1681-1690
66. Powell IB, Achen MG, Hillier AJ, Davidson BE. 1988. A simple and rapid method for genetic transformation of lactic streptococci by electroporation. Appl. Environ. Microbiol. 54:655660.
67. Qin J, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59-65.
68. Reyes Escogido ML, De León Rodríguez A, Barba de la Rosa AP. 2007. A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol. Lett. 29:1249-1253.
69. Riedel CU, et al. 2007. Construction of p16Slux, a novel vector for improved bioluminescent labeling of gram-negative bacteria. Appl. Environ. Microbiol. 73:7092-7095.
70. Riedel CU, et al. 2007. Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl. Environ. Microbiol. 73:3091-3094.
71. Rossi M, Brigidi P, Gonzalez Vara y, Rodriguez A, Matteuzzi D. 1996. Characterization of the plasmid pMB1 from Bifidobacterium longum and its use for shuttle vector construction. Res. Microbiol. 147:133-143.
72. Rossi M, Brigidi P, Matteuzzi D. 1998. Improved cloning vectors for Bifidobacterium spp. Lett. Appl. Microbiol. 26:101-104.
73. Rossi M, Brigidi P, Matteuzzi D. 1997. An efficient transformation system for Bifidobacterium spp. Lett. Appl. Microbiol. 24:33-36.
74. Ruiz L, et al. 2012. Controlled gene expression in bifidobacteria by use of a bile-responsive element. Appl. Environ. Microbiol. 78:581-585.
75. Ruiz L, et al. 1 February 2012. A bile-inducible membrane protein mediates bifidobacterial bile resistance. Microb. Biotechnol. doi: 10.1111/ j.1751-7915.2011.00329.x. [Epub ahead of print.]
76. Sangrador-Vegas A, Stanton C, van Sinderen D, Fitzgerald GF, Ross RP. 2007. Characterization of plasmid pASV479 from Bifidobacterium pseudolongum subsp. globosum and its use for expression vector construction. Plasmid 58:140-147.
77. Sgorbati B, Scardovi V, Leblanc DJ. 1982. Plasmids in the genus Bifidobacterium. J. Gen. Microbiol. 128:2121-2131.
78. Shkoporov AN, Efimov BA, Khokhlova EV, Kafarskaia LI, Smeianov VV. 2008. Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors. Biotechnol. Lett. 30:1983-1988.
79. Shkoporov AN, et al. 2008. Characterization of plasmids from human infant Bifidobacterium strains: sequence analysis and construction of E. coli-Bifidobacterium shuttle vectors. Plasmid 60:136-148.
80. Takata T, et al. 2006. Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model. J. Gene Med. 8:1341-1346.
81. Tan Y, Xu D, Li Y, Wang X. 2012. Construction of a novel sacB-based system for marker-free gene deletion in Corynebacterium glutamicum. Plasmid 67:44-52.
82. Tanaka K, Samura K, Kano Y. 2005. Structural and functional analysis of pTB6 from Bifidobacterium longum. Biosci. Biotechnol. Biochem. 69:422-425.
83. Taniguchi S, et al. 2010. Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci. 101:1925-1932.
84. Tannock GW. 2010. Analysis of bifidobacterial populations in bowel ecology studies, p 1-16. In Mayo B, van Sinderen D (ed), Bifidobacteria: genomics and molecular aspects. Caister Academic Press, Norfolk, United Kin dom.
85. Wu G, et al. 2011. Application of GFAT as a novel selection marker to mediate gene expression. PLoS One 6:e17082. doi:10.1371/journal. pone.0017082.
86. Xu Y-F, et al. 2007. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 14:151-157.
87. Yamamoto S, et al. 2010. Genetically modified Bifidobacterium displaying Salmonella antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 28:6684-6691.
88. Yao J, et al. 2011. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Mol. Pharm. 8:488-497.
89. Yasui K, et al. 2009. Improvement of bacterial transformation efficiency using plasmid artificial modification. Nucleic Acids Res. 37:e3.
90. Yildirim Z, Winters DK, Johnson MG. 1999. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacteriu bifidum NCFB 1454. J. Appl. Microbiol. 86:45-54.
91. Yu Z, et al. 2012. Bifidobacterium as an oral delivery carrier of interleukin- 12 for the treatment of Coxsackie virus B3-induced myocarditis in the Balb/c mice. Int. Immunopharmacol. 12:125-130.
92. Zomer A, et al. 2009. An interactive regulatory network controls stress response in Bifidobacterium breve UCC2003. J. Bacteriol. 191:7039-7049.